SCHEMBL1207932

SCHEMBL1207932

CN(C(=O)S(N)(=O)=O)c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 18/20 0.80
PTK2B Q14289 15/20 0.80
AURKA O14965 2/20 0.80
PLK4 O00444 1/20 0.80
PDPK1 O15530 1/20 0.80
DAPK3 O43293 1/20 0.80
JAK2 O60674 1/20 0.80
ROCK2 O75116 1/20 0.80
STK16 O75716 1/20 0.80
PRKD3 O94806 1/20 0.80
MAP4K4 O95819 1/20 0.80
PAK4 O96013 1/20 0.80
CHEK2 O96017 1/20 0.80
NTRK1 P04629 1/20 0.80
PRKCG P05129 1/20 0.80
INSR P06213 1/20 0.80
LCK P06239 1/20 0.80
FYN P06241 1/20 0.80
CDK1 P06493 1/20 0.80
LYN P07948 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pf-00562271 SCHEMBL29637167 0.89 PTK2 (1.00) PTK2PTK2BAURKAPLK4PDPK1
Pf-00562271 SCHEMBL29381854 0.89 PTK2 (1.00) PTK2PTK2BAURKAPLK4PDPK1
Pf-00562271 SCHEMBL1206959 0.89 PTK2 (1.00) PTK2PTK2BAURKAPLK4PDPK1
Pf-00562271 SCHEMBL21062022 0.88 PTK2 (0.99) PTK2PTK2BAURKAPLK4PDPK1
Pf-00562271 SCHEMBL29496512 0.88 PTK2 (0.99) PTK2PTK2BAURKAPLK4PDPK1
SCHEMBL5504547 0.86 PTK2 (0.84) PTK2PTK2BAURKAPLK4PDPK1
SCHEMBL5501091 0.86 PTK2 (0.84) PTK2PTK2BAURKAPLK4PDPK1
SCHEMBL20459263 0.85 PTK2 (0.78) PTK2PTK2BAURKAPLK4PDPK1
Pf-00562271 SCHEMBL20471937 0.85 PTK2 (1.00) PTK2PTK2BAURKAPLK4PDPK1
SCHEMBL5185817 0.84 PTK2 (0.89) PTK2PTK2BAURKAPLK4PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110033441-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033441-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH MKI67, TK2, DPYD PTK2 2208/4885PTK2B 1592/4885AURKA 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.